AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05692635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI of the Brain
Description: An MRI brain scan with and without gadolinium contrast. Three scans are planned for each participant.
Study NCT06399536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized ANH
Description: Participants will undergo individualized ANH based on the West China Liu's Score after anesthetic induction. The decision of autologous blood transfusion or allogeneic red cell transfusion will be made according to the West China Liu's Score.
Study NCT05039021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONIC 1100 Shears
Description: HARMONIC 1100 Shears is used for vessel transection according to instructions for use.
Study NCT04932941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP1032
Description: Hard gelatin capsules for oral administration.
Study NCT04932941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matched to MP1032 for oral administration.
Study NCT04224727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Commitment Contract
Description: A group contract where the primary individual, who will be tracked by the study, can invite peers to join the contract and form their group. To initiate a contract, a user must choose: the stakes, start date, and (for weight loss contracts) target weight, and and, optionally, to allow other members to have the power to invite other people to join the group.
Study NCT04224727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Monetary Rewards
Description: Individuals eligible for a $100 monetary reward (incentive) following verified smoking cessation or weight loss.
Study NCT04224727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Commitment Contract
Description: Individuals will have the opportunity to create an individual commitment contract to quit smoking. They will have the option to set the stakes, start date, and (for weight loss contracts) target weight.
Study NCT04224727 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: In the initial survey, participants will receive additional information treatments on the likelihood of success of the different incentives and contracts, with the goal of shifting naives to sophisticates.
Study NCT06236568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-HOPE machine perfusion
Description: use of the device
Study NCT06236568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Liver transplantation for HCC within Milan criteria
Study NCT06236568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver transplantation
Description: Liver transplantation for HCC within Milan criteria
Study NCT05692635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Before each MRI, participants will give about a teaspoon of blood to test for clinical purposes.
Study NCT05393063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127
Description: Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）
Study NCT04588688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor.
Study NCT05555394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Body Awareness Therapy
Description: The intervention will be twice a week during 12 weeks. It lasts 90 min of movements of daily life, massage and self-reflections.
Study NCT05555394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise
Description: It consists in stretching movements of whole body
Study NCT05692635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: Participants will fill out two questionnaires about their health. These questionnaires will tell investigators about any symptoms participants may be having that might be related to cancer spreading to their brain. This will take about 10-15 minutes to complete.
Study NCT05692635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given intravenously
Study NCT05171582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 1 (Test group)
Description: After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the test group will be full-filled either with bovine bone substitute with hyaluronic acid (Cerabone plus). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
Study NCT05171582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery 2 (Control group)
Description: After local anaesthesia, a full-mucoperiosteal flap will be evaluated. After granulation tissue is removed by using titanium or graphite curettes and implant surface decontamination will be performed using photodynamic therapy. Thereafter, the peri-implant bone defects in the control group will be full-filled either with bovine bone substitute (Cerabone). Collagen dermal matrix (Mucoderm) will be inserted instead of a collagen membrane. Mucoderm will be fixed with 5.0 resorbable sutures. The flap will be coronally positioned and sutured with 5.0 non-resorbable sutures, respectively.
Study NCT04949178 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study.
Study NCT04736108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg orally daily for 24 weeks before radical prostatectomy
Study NCT04736108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 5 mg oral low dose prednisone, once daily
Study NCT04736108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 10.8 mg goserelin hypodermic once per 12 weeks
Study NCT06296524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Footcore exercises and conventional therapy
Description: 30 minutes exercises protocol will be provided
Study NCT06296524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional therapy will be provided.
Study NCT04776265 — intervention group
Intervention type: OTHER
Intervention: Evaluation of therapeutical approach after ASCT
Description: Evaluation of therapeutical approach after ASCT
Study NCT05172752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Citizen Scientist Training Program
Description: Citizen Scientist Training Program Participants is a three year training and in-home sampling program for disinfection byproducts. Participants will be trained and assessed based on their experience in the training program.
Study NCT05172752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stakeholder Consultation Core Program
Description: Stakeholder Consultation Core Program Participants is a five year assessments where participants will participate in quarterly meetings and deliberative activities related to disinfection byproducts. Participants will be assessed based on their experience in the program.
Study NCT05033938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Mobilization Protocol
Description: Subjects will be placed in a bulky soft dressing immediately after surgery. They will be made non-weight bearing, but active and passive motion of digits, forearm, elbow, and shoulder will be allowed with light functional tasks permitted as tolerated. Wrist motion within the soft dressing will be permitted as tolerated by patient. On postoperative day 3, patients will be advised to remove the dressing at home and begin home hand/wrist therapy. They will use a removable Velcro wrist splint for nighttime wear and strenuous activity. This splint can be removed during normal activities of daily living and therapy.
Study NCT05033938 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Mobilization Protocol
Description: Subjects will be placed in a plaster volar resting splint. They will be made non-weight bearing, with use of digits for light functional tasks permitted. They will be given home exercises for their fingers but will not yet resume wrist motion
Study NCT05521061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2-fucosyllactose
Description: Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
Study NCT05521061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 2-fucosyllactose
Description: Volunteers will be visited to provide the investigational product/placebo to the diets of the patients included in the study for 3 months, and the use of the investigational product/placebo will be monitored. Parents will be trained by their fellows to provide synthetic breast milk oligosaccharides/placebo, the products to be used in the study will be provided by the scholars on a weekly basis, and their daily intake and possible problems will be monitored through weekly interviews. In this study, it is planned to supplement the diet of the placebo group with 1.5 g/day maltodextrins to approximately half of the diet and to supplement the other half with 3 g/day maltodextrins, after the group was randomized within itself. Effects of these doses on metabolic control are not expected. Maltodextrine is in powder form, its dosage of up to 3 g/day has a negligible effect on blood glucose, it has a neutral taste, it is cheap and easy to find, and it is safe and ineffective.
Study NCT04822376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ansuvimab
Description: Human monoclonal antibody to Zaire strain GP (EBOV GP)
Study NCT04822376 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ervebo
Description: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
Study NCT04822376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
Study NCT05516927 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Freenome Test
Description: Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
Study NCT05430880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: impact of fluid challenge on the cardiac index and CO2 respiratory parameters analysis (VCO2, EtCO2)
Description: Preliminary daily data will record: demographic, ventilatory (tidal volume, FiO2, positive expiratory pressure, compliance, respiratory rate, I/E ratio) and biological parameters (fibrinogen, CRP, leukocytes count, PaO2, PvO2, PaCO2, PvCO2, CO2gap, arterial lactate, ScvO2, platelets count)~1. st step CO2 record (between Time-6minutes and T0; T0 corresponding to fluid challenge) VCO2 and EtCO2 (End-tidal CO2) automated measurement by Hamilton module. Average VCO2 obtained before fluid challenge.~   CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli.~2. nd step: Crystalloid (ringer lactate) filling 500mL in 5 minutes~3. rd step CO2 record (between T+5min and Time+11minutes): VCO2 and EtCO2: automated measurement by Hamilton module. Average VCO2 obtained after fluid challenge.~CI (cardiac index): measurement by calibration of the PiCCO module with 3 cold boli
Study NCT06354140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; > 1.5m2, use 120mg. Treatment for 1 year
Study NCT04759066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALiX
Description: HEALiX is a non-restraint patient safety device
Study NCT05684094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension and advance
Description: Participants in the sleep extension and advance condition will maintain a stable sleep schedule that extends sleep duration and advances bedtime by 90 min relative to weekday bedtime. This chronotherapeutic manipulation will include blocking phase-delaying light in the evening using goggles with orange lenses (blue blockers) beginning 2 h prior to bedtime, and 30 min of 506 lux blue-green light exposure in the morning beginning at rise time using bright light goggles (ReTimer Pty Ltd., Australia). Schedule and chronotherapy adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study NCT05684094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular sleep duration and timing
Description: Participants in the regular sleep duration and timing condition will keep a stable sleep schedule that matches their typical weekday sleep opportunity and timing. Schedule adherence will be reinforced using motivational techniques (e.g., securing motivation, preplanning, problem-solving), requiring participants to text the study coordinator and complete morning assessments at rise time, and monetary incentives.
Study NCT05362110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once daily for 8 weeks orally.
Study NCT05362110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2002
Description: Take it once daily for 8 weeks orally.
Study NCT05362110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study NCT05362110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2004
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study NCT05876013 — intervention group
Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Randomized between hamstring and patellar tendon graft
Study NCT06375668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The patients who give their consent to take part in this study, will receive one time per day for a period of 12 month a capsule containing ten billions of Lactobacillus plantarum (LP 140 NORDBIOTIC™) and Lactobacillus paracasei (LPC 100 NORDBIOTIC™).
Study NCT06375668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients who give their consent to take part in this study, will receive one time per day for a period of 12 months a capsule containing maltodextrin.
Study NCT05421364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of autologous peripheral blood mononuclear cells (PBMC)
Description: Approximately 9 ml blood from each patient will be collected on the day of the LH peak by peripheral venipuncture using a 21G butterfly catheter affixed via vacutainer to negative pressure receiving tubes (BD vacutainer acid-citrate-dextrose (ACD-A), REF:366645). PBMC will be isolated by density gradient centrifugation in room-temperature centrifuge set to 400 g for 25 min. PBMCs (1x106cells/ml) suspended in RPMI 1640 supplemented with 10% HSA will be incubated in the presence of 10 IU/ml hHCG for 48 h. On day 2 after LH peak, fresh PBMCs (1x107 cells) will be also obtained from the same patients, these fresh PBMCs will be immediately combined with the 2-day cultured PBMC and suspended in PBS (2x107 cells/200µl). This cell suspension will be carefully introduced in the uterine cavity by catheter on day 2 after LH peak.
Study NCT04928703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine IV administration
Study NCT06643507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: regenerative properties
Study NCT06643507 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALB-PRF
Description: regenerative properties
Study NCT05200832 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Description: Participants will be asked to complete an online questionnaire about their health and quality of life since the start of the pandemic.
Study NCT05200832 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interview
Description: 20 participants (10 from each group) will be randomly selected to participate in a semi-structured interview focusing on their perception of their health and quality of life since the start of the pandemic.
Study NCT04574011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Description: Raise the patient's lower limb at a 45 degree angle while lying down
Study NCT06246175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 injection
Study NCT06192277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Patients are screened to confirm they are low risk for a penicillin allergy
Study NCT06192277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Penicillin
Description: Low risk participants are given a low-dose of oral penicillin followed by 60 minutes of observation
Study NCT06192277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose Penicillin
Description: Participants who have taken the low dose of oral penicillin and have had no reaction are provided a second higher dose of penicillin (250mg) and observed for 60 minutes.
Study NCT06192277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remove allergy label
Description: Participants who have no reaction after 28 days have their penicillin allergy label removed from their electronic medical record and hospital record.
Study NCT04972292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of codeine 30 mg/dipyrone 500 mg
Description: Group 1: receive one (1) experimental drug tablet (FCD of codeine 30mg/dipyrone 500mg) + one (1) Tylex® placebo.
Study NCT04972292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylex
Description: Group 2: receive one (1) Tylex® tablet (codeine 30 mg/paracetamol 500 mg) + one (1) FDC placebo tablet
Study NCT05001256 — intervention group
Intervention type: OTHER
Intervention: questionnaire study
Description: Participants will be surveyed through face-to-face interviews.
Study NCT06162858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IMU (Inertial Measurement Devices)
Description: Functional placing and reaching of objects of different weights on different heights
Study NCT06034665 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: All patients will be included in the exercise program for their symptoms regarding knee osteoarthritis for 15 sessions.
Study NCT06668597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational educational program to improve sleep quality in OSA patients through adherence to CPAP
Description: Phase 1 (Pre-adaptation Psychoeducation): The participant will be shown, within two days prior to the home visit by the provider, which usually takes place within three days of the visit with the pulmonologist, the necessary materials (device, masks, and tubing), along with an educational video on the topic of OSA (duration 25 minutes); Phase 2 (Motivational Interview): Following the first night of titration and use of the CPAP, the participant will be contacted by phone for a brief motivational interview (duration 25 minutes); Phase 3 (Psychological Support Interview): One week after the provider's intervention and the start of the CPAP adaptation period, the participant will be contacted again for a support interview regarding the adaptation process to CPAP (duration 40 minutes). The first week of adaptation is considered a high-risk period for abandonment of device use; Phase 4 (Monitoring Interview): Two weeks after the provider's intervention and the start o
Study NCT04371952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: comparison of doxycycline 200 mg/day to placebo
Study NCT04371952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : lactose, 380 mg/gélule
Study NCT06357754 — intervention group
Intervention type: BIOLOGICAL
Intervention: Idecabtagene vicleucel
Description: As per product label